IMMUNOMEDICS INC
Form SC 13G/A
February 13, 2019

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549
SCHEDULE 13G/A
Under the Securities Exchange Act of 1934
(Amendment No. 3)*
Immunomedics, Inc. (Name of Issuer)
Common Stock, Par Value \$0.01 Per Share (Title of Class of Securities)
452907108 (CUSIP Number)
December 31, 2018 (Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

x Rule 13d-1(b)

o Rule 13d-1(c)

o Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Page 2 of 8 Pages

SCHEDULE 13G/A

CUSIP No. 452907108

NAME OF REPORTING PERSONS 1 OrbiMed Advisors LLC CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP 2 (a) o (b) o SEC USE ONLY 3 CITIZENSHIP OR PLACE OF ORGANIZATION 4 Delaware **SOLE VOTING POWER** 5 0 NUMBER OF **SHARES** SHARED VOTING POWER **BENEFICIALLY** 6 OWNED BY 977,903 **EACH** SOLE DISPOSITIVE POWER **REPORTING** 7 **PERSON** 0 WITH SHARED DISPOSITIVE POWER 8 977,903 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 9 977,903 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN o **SHARES** 10 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 11 0.51% TYPE OF REPORTING PERSON 12 IA

Page 3 of 8 Pages

SCHEDULE 13G/A

CUSIP No. 452907108

NAME OF REPORTING PERSONS 1 OrbiMed Capital LLC CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP 2 (a) o (b) o SEC USE ONLY 3 CITIZENSHIP OR PLACE OF ORGANIZATION 4 Delaware **SOLE VOTING POWER** 5 0 NUMBER OF **SHARES** SHARED VOTING POWER **BENEFICIALLY** 6 **OWNED BY** 4,089,500 **EACH** SOLE DISPOSITIVE POWER **REPORTING** 7 **PERSON** 0 WITH SHARED DISPOSITIVE POWER 8 4.089,500 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 9 4,089,500 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN o **SHARES** 10 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 11 2.15% TYPE OF REPORTING PERSON 12 IA

CUSIP No. 452907108	SCHEDULE 13G/A	Page 4 of 8 Pages
Item 1. (a) Name of Issuer:		
Immunomedics, Inc.		
	(b) Address of Issuer's P	rincipal Executive Offices:
300 The American Road		
Morris Plains, New Jersey 07950		
Item 2.	(a) Na	nme of Person Filing:
OrbiMed Advisors LLC		
OrbiMed Capital LLC		
	(b) Address of Pri	ncipal Business Office:
601 Lexington Avenue, 54th Floor		
New York, NY 10022		
	(0	c) Citizenship:
Please refer to Item 4 on each cover	r page for each Reporting Person.	
	(d) Title of	Class of Securities:
Common Stock, Par Value \$0.01 Pe	er Share	
	((e) CUSIP No.:
452907108		

CUSIP No. 452907108

SCHEDULE 13G/A

Page 5 of 8 Pages

Item 3.

 $\label{lem:condition} OrbiMed\ Advisors\ LLC\ ("Advisors")\ and\ OrbiMed\ Capital\ LLC\ ("Capital")\ are\ investment\ advisors\ in\ accordance\ with\ ss. 240.13d-1(b)(1)(ii)(E).$

CUSIP No. 452907108	SCHEDULE 13G/A	Page 6 of 8 Pages		
Item 4. Ownership:				
Information with respect to the Reitems (5) - (9) and (11) of the cover		f December 31, 2018 is incorporated by reference to		
Item 5. Ownership of Five Perc	ent or Less of a Class.			
If this statement is being filed to rebeneficial owner of more than five	_	nereof the reporting person has ceased to be the s, check the following [X].		
Item 6. Ownership of More Tha	nn Five Percent on Behalf of A	nother Person.		
Not Applicable.				
Item 7. Identification and Classi the Parent Holding Company or	=	ch Acquired the Security Being Reported on by		
Not Applicable.				
Item 8. Identification and Classi	fication of Members of the Gr	oup.		
Not Applicable.				
Item 9. Notice of Dissolution of 0	Group.			
Not Applicable.				
Item 10. Certification.				

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect

of changing or influencing the control of the issuer of the securities and were not acquired and are not held in

connection with or as a participant in any transaction having that purpose or effect.

CUSIP No. 452907108

SCHEDULE 13G/A

Page 7 of 8 Pages

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 12, 2019

OrbiMed Advisors LLC

By:/s/ Jonathan T. Silverstein

Name: Jonathan T. Silverstein

Title: Member of OrbiMed Advisors LLC

By:/s/ Sven H. Borho

Name: Sven H. Borho

Title: Member of OrbiMed Advisors LLC

By:/s/ Carl L. Gordon

Name: Carl L. Gordon

Title: Member of OrbiMed Advisors LLC

OrbiMed Capital LLC

By:/s/ Jonathan T. Silverstein

Name: Jonathan T. Silverstein

Title: Member of OrbiMed Capital LLC

By:/s/ Sven H. Borho

Name: Sven H. Borho

Title: Member of OrbiMed Capital LLC

By:/s/ Carl L. Gordon

Name: Carl L. Gordon

Title: Member of OrbiMed Capital LLC

CUSIP No. 452907108

SCHEDULE 13G/A

Page 8 of 8 Pages

EXHIBIT A

JOINT FILING AGREEMENT

The undersigned hereby agree that the Statement on this Schedule 13G/A dated February 12, 2019 (the "Schedule 13G/A"), with respect to the Common Stock, par value \$0.01 per share, of Immunomedics, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that this Agreement shall be included as an Exhibit to this Schedule 13G/A. Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13G/A, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.

IN WITNESS WHEREOF, the undersigned have executed this Agreement as of February 12, 2019.

OrbiMed Advisors LLC

By:/s/ Jonathan T. Silverstein

Name: Jonathan T. Silverstein

Title: Member of OrbiMed Advisors LLC

By:/s/ Sven H. Borho Name: Sven H. Borho

Title: Member of OrbiMed Advisors LLC

By:/s/ Carl L. Gordon Name: Carl L. Gordon

Title: Member of OrbiMed Advisors LLC

OrbiMed Capital LLC

By:/s/ Jonathan T. Silverstein Name: Jonathan T. Silverstein

Name. Johannan 1. Shverstein

Title: Member of OrbiMed Capital LLC

By:/s/ Sven H. Borho Name: Sven H. Borho

Title: Member of OrbiMed Capital LLC

By:/s/ Carl L. Gordon Name: Carl L. Gordon

Title: Member of OrbiMed Capital LLC

The Statement on this Schedule 13G/A dated February 12, 2019 with respect to the Common Stock of Immunomedics, Inc. is filed by OrbiMed Advisors LLC and OrbiMed Capital LLC in accordance with the provisions of Rule 13d-1(b) and Rule 13d-1(k), respectively, as investment advisors (IA).